Fabrizio Pane
Fabrizio Pane
Verified email at unina.it
TitleCited byYear
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ...
Journal of clinical oncology 27 (35), 6041, 2009
14432009
Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection …
J Gabert, E Beillard, VHJ Van der Velden, W Bi, D Grimwade, ...
Leukemia 17 (12), 2318, 2003
14302003
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood 122 (6), 872-884, 2013
13992013
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ...
Clinical Cancer Research 12 (24), 7374-7379, 2006
4982006
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)[see comments]
F Pane, F Frigeri, M Sindona, L Luciano, F Ferrara, R Cimino, G Meloni, ...
Blood 88 (7), 2410-2414, 1996
4851996
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European …
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...
Blood 118 (5), 1208-1215, 2011
4502011
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression …
S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ...
Journal of clinical oncology 23 (18), 4100-4109, 2005
4162005
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ...
New England Journal of Medicine 372 (5), 426-435, 2015
4002015
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and …
S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, DW Kim, ...
Blood 112 (8), 3330-3338, 2008
3352008
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
3232011
Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia …
D Diverio, V Rossi, G Avvisati, S DeSantis, A Pistilli, F Pane, G Saglio, ...
Blood 92 (3), 784-789, 1998
3191998
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in …
JE Cortes, M Baccarani, F Guilhot, BJ Druker, S Branford, DW Kim, ...
Journal of Clinical Oncology 28 (3), 424, 2010
2752010
IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative …
G Martinelli, I Iacobucci, CT Storlazzi, M Vignetti, F Paoloni, D Cilloni, ...
Journal of Clinical Oncology 27 (31), 5202-5207, 2009
2512009
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...
Blood 114 (24), 4933-4938, 2009
2372009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
M Baccarani, G Rosti, F Castagnetti, I Haznedaroglu, K Porkka, ...
Blood 113 (19), 4497-4504, 2009
2132009
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol
M Mancini, D Scappaticci, G Cimino, M Nanni, V Derme, L Elia, A Tafuri, ...
Blood 105 (9), 3434-3441, 2005
2122005
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia …
I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ...
Blood 114 (10), 2159-2167, 2009
2002009
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ...
haematologica 92 (9), 1173-1179, 2007
1932007
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
F Ferrara, F Morabito, B Martino, G Specchia, V Liso, F Nobile, P Boccuni, ...
Journal of Clinical Oncology 18 (6), 1295-1300, 2000
1772000
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia
B Falini, MP Martelli, N Bolli, R Bonasso, E Ghia, MT Pallotta, D Diverio, ...
Blood 108 (6), 1999-2005, 2006
1662006
The system can't perform the operation now. Try again later.
Articles 1–20